Interim18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation – where do we stand?
- 4 October 2009
- journal article
- other
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 50 (11), 1753-1756
- https://doi.org/10.3109/10428190903308056
Abstract
Interim 18F-fluorodeoxyglucose positron emission tomography performed early during the course of therapy in diffuse large B-cell lymphoma is highly predictive of outcome and now used in many clinical trials to validate risk-adapted strategies. However, interpretation criteria of interim PET are not yet appropriately defined for the evaluation of tumor response and chemosensitivity. From the results of our studies, a quantitative approach based on SUVmax reduction between baseline PET (PET0) and interim PET demonstrated a higher predictive value than visual analysis when PET was performed at two cycles (PET2) but was equivalent to visual analysis at four cycles (PET4). The SUVmax reduction index at PET2 seems to be the best predictor of the response compared to clinical or molecular prognostic indices. When visual analysis is necessary, the use of an online independent reading network may solve the interobserver variability, but the hurdles of visual analysis deserve an international validation study to confirm the newly proposed criteria.Keywords
This publication has 16 references indexed in Scilit:
- Development and Application of a Real-Time On-Line Blinded Independent Central Review of Interim Pet Scans to Determine Treatment Allocation in Lymphoma TrialsJournal of Clinical Oncology, 2009
- Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic ReviewJournal of Clinical Oncology, 2009
- The Case Against Heavy PETingJournal of Clinical Oncology, 2009
- Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of ChemotherapyJournal of Nuclear Medicine, 2009
- High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimensAnnals Of Oncology, 2009
- FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphomaCurrent Opinion in Oncology, 2008
- Early interim PET scan in Hodgkin lymphoma: Where do we stand?Leukemia & Lymphoma, 2008
- Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphomaHaematologica, 2007
- Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaJournal of Clinical Oncology, 2007
- [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcomeBlood, 2005